Effectiveness of vaccines to prevent antibiotic prescribing for acute respiratory tract infections in high risk adults
- Funded by Wellcome Trust
- Total publications:0 publications
Grant number: 219763/Z/19/Z
Grant search
Key facts
Disease
UnspecifiedStart & end year
20212023Known Financial Commitments (USD)
$243,077.1Funder
Wellcome TrustPrincipal Investigator
Bette LiuResearch Location
AustraliaLead Research Institution
University of New South WalesResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Characterisation of vaccine-induced immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Older adults (65 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
In high income countries the greatest use of antibiotics is in community (primary care) settings in the context of acute respiratory tract infections. Within these settings, both the very young, the very old and those with respiratory conditions such as asthma and chronic obstructive pulmonary disease are known to be the greatest antibiotic users. While there are a number of vaccines routinely provided that protect against acute respiratory tract infections, there is limited empirical data quantifying the potential benefit of vaccines to reduce antibiotic use for respiratory tract infections, particularly in adult populations. In this project we will use a large-scale database of electronic general practice records to quantify, in older adults, the effectiveness of influenza, pertussis and pneumococcal vaccines in reducing primary care presentations for acute respiratory tract infections and subsequent antibiotic prescribing. We will focus on high risk groups defined by age and/or co-morbidity (asthma and chronic obstructive pulmonary disease). We will use these estimates of vaccine effectiveness to model the absolute reductions in antibiotic use that could be obtained by increasing vaccine coverage in different adult sub-groups. This evidence will enable policymakers to better prioritise strategies to increase uptake of these vaccines.